These findings showed that sHLA-G, IL-6, and IL-10 plasma levels had a good discriminatory effect between cervical cancer patients and healthy controls, suggesting that sHLA-G could be used as a potential biomarker of cervical cancer. This evidence concerns the gene IL6 and cervical cancer.